Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
82.90
-1.80 (-2.13%)
Apr 24, 2025, 1:30 PM CST
-54.33%
Market Cap 10.45B
Revenue (ttm) 32.04M
Net Income (ttm) -82.55M
Shares Out 126.06M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,068
Average Volume 204,098
Open 84.70
Previous Close 84.70
Day's Range 82.50 - 85.00
52-Week Range 73.00 - 195.50
Beta 0.56
RSI 43.27
Earnings Date Apr 17, 2025

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6617
Full Company Profile

Financial Performance

In 2024, Gongwin Biopharm Holdings's revenue was 32.04 million, an increase of 69.39% compared to the previous year's 18.92 million. Losses were -82.55 million, -10.31% less than in 2023.

Financial Statements

News

There is no news available yet.